Introduction
As in other tissues, mitochondria play many important roles in hematopoietic cell homeostasis, including the production of adenosine triphosphate (ATP) by the process of oxidative phosphorylation, the release of death-promoting factors upon apoptotic stimuli and a variety of metabolic pathways such as heme synthesis. Mitochondria could also play a role in specific pathways of hematopoietic cell differentiation through caspase activation. Alterations of these mitochondrial functions play a pathophysiological role in a variety of hematological diseases, especially those affecting erythroid lineage such as inherited dyserythropoiesis and sideroblastic anemias and acquired, low-grade myelodysplastic syndromes. In these diseases, compromised mitochondrial functions could be related to mitochondrial genome mutations, alterations in iron (Fe) mitochondrial metabolism or exacerbation of physiological pathways involving caspases, leading to activation of the mitochondrial pathway to apoptotic cell death. Mitochondria also plays a central role in the apoptotic response of transformed hematopoietic cells when exposed to cytotoxic drugs, although oncogenesisassociated changes at the mitochondrial level can induce resistance to apoptosis induced by a variety of these drugs. Owing to their central role in cell death, mitochondria now appear as a potential target for killing malignant cells. This review will evoke several examples in which mitochondria play a pathophysiological role in hematopoietic diseases, the role of these organelles in hematopoietic cell differentiation and response to cytotoxic agents and the various strategies currently tested to use mitochondria as a target to treat malignant hematopoietic diseases.
Mitochondrial DNA mutations in hematopoietic cell aging and diseases
Together with the nucleus, mitochondria are the only organelles of animal cells that contain DNA as well as their own machinery for RNA and protein synthesis. Mitochondrial DNA (mtDNA) is a double-stranded circular molecule present as 2-10 copies in each mitochondrion. Cells contain thousands of mtDNA molecules that distinguish from nuclear DNA (nDNA) by several characteristics, including maternal inheritance, a modified genetic code, a paucity of introns, the lack of histone protection and the limited efficacy of the repair system. These two later characteristics, together with its proximity to radical oxygen species (ROS) generation due to oxidative phosphorylation for ATP production, may account to the 10-to 20-fold higher mutation rate in mtDNA compared with nDNA (Yakes and Van Houten, 1997) . In addition, multiple species of mtDNA can coexist in a single cell, a condition called heteroplasmy.
Somatically acquired mtDNA mutations are attributable to mitochondrial oxidative damage, which increases with age. Single mutant mtDNA molecules have long been assumed to be lost by dilution in rapidly dividing tissues such as bone marrow. Actually, agedependent accumulation of mtDNA mutations, and expansion of mutated mtDNA molecules from heteroplasmy to homoplasmy (Chinnery et al., 2002) , appear to be relatively common in adult CD34
þ marrow progenitors and presumably stem cells (Ogasawara et al., 2005) . Thus, age-associated mtDNA mutations lead to marked heterogeneity among adult bone marrow and peripheral blood CD34 þ cells, not present in umbilical cord blood. Mitochondrial DNA variant sequences were proposed as natural genetic markers for determining the contribution of individual stem cells to blood production. In addition, mtDNA changes fixed in leukemic cells might provide a simple method for monitoring minimal residual disease (He et al., 2003) .
Integrity of mtDNA involves a DNA polymerase whose catalytic subunit is encoded by a nuclear gene. Knock-in mice that express a proof-reading-deficient version of the catalytic subunit of this polymerase develop a MtDNA mutator phenotype with a significant increase in the level of point mutations, as well as increased amounts of deletions. These events are associated with reduced lifespan and premature onset of aging-related symptoms, including anemia (Trifunovic et al., 2004) . Interestingly, the increase in mtDNA mutations observed in these mice does not depend on an increase in oxidative phosphorylation (Kujoth et al., 2005) .
Lesions in mtDNA and mitochondrial dysfunction contribute to numerous human diseases. Large deletions in mtDNA are the hallmark of Pearson's syndrome, a rare congenital disorder with lactic acidosis, pancreatic insufficiency and sideroblastic anemia (Pearson et al., 1979; Rotig et al., 1991) (Table 1) . Sideroblastic anemias are characterized by Fe overload in the mitochondria that are revealed by Perls staining as a ring around the nucleus in basophilic and polychromatophilic erythroblasts (Figure 1) . Transmission electron microscopy analysis of bone-marrow cells in infants with inherited sideroblastic anemia often reveals features of apoptosis with condensed nuclear chromatin and fragmentation of the erythroid cells associated to Fe deposition in mitochondria (EM Cramer, M Fontenay, Figure 1 ). Somatically acquired mtDNA mutations were also reported in apparently acquired sideroblastic anemia and in myelodysplastic syndromes (Gattermann, 2000) . For exemple, in bone-marrow cells from patients with a refractory anemia with ring sideroblasts (RARS), mutations were identified in the genes encoding the mitochondrial tRNA for leucine, the subunit I of cytochrome c oxidase and the cytochrome b (Gattermann et al., 1996 (Gattermann et al., , 1997 Reddy et al., 2002) . The link between these mutations and the disease remains highly controversial as a comparative study did not demonstrate an increase in the frequency of mtDNA mutations in a large cohort of myelodysplastic syndrome patients compared to age-matched normal individuals (Shin et al., 2003) .
A current speculation is that age-related mtDNA mutations in CD34 þ clones could lead to derangement of marrow function in older individuals (Shin et al., 2004) . Whether these mutations are associated with abnormal oxidative phosphorylation measured in myelodysplastic syndrome bone-marrow samples is a matter of discussion (Bowen and Peddie, 2002; Matthes et al., 2002) . At least in older patients, they could also play a role in excessive apoptosis that characterizes low-grade myelodysplastic syndromes (Bouscary et al., 1997) as mice with defective mtDNA polymerase exhibit apoptosis in excess in several rapidly growing tissues (Kujoth et al., 2005) and in vivo apoptosis is increased in cells lacking mtDNA (Wang et al., 2001) .
Role of mitochondrial iron metabolism in hematological diseases
Iron plays a crucial role in many facets of mitochondrial metabolism. Trafficking and storage of Fe in the (Napier et al., 2005) . Iron is transported within the serum bound to transferrin (Tf) that binds the Tf receptor (TfR1). Receptor-mediated endocytosis of the Tf-TfR1 complex is followed by the release of Fe from Tf in the endosomal compartment. Iron can then be directed to numerous sites within the cell including the mitochondria or incorporated into cytosolic storage molecules such as ferritin (Figure 2 ). In hemoglobin synthesizing erythroid cells, the Fe trafficking specifically targets the mitochondria but how Fe is directed from the endosome to the mitochondrion remains unclear. In the mitochondrion, Fe can be used in a variety of ubiquitous metabolic pathways, including heme synthesis and various Fe-sulfur (Fe-S) cluster biogenesis (Lill and Kispal, 2000) . The biosynthesis of heme, which occurs in all cells, involves eight steps, four of which occur in the mitochondria.
The first and rate-limiting step of the pathway, which occurs in the mitochondrial matrix, is catalysed by d-aminolevulinic acid synthase (ALAS), an enzyme encoded by two different genes. Whereas ALAS1 is expressed ubiquitously, the expression of ALAS2 is specific to erythroid cells. Various mutations in ALAS2, located at chromosome Xp11.21, have been reported in patients with X-linked sideroblastic anemia (XLSA), the most common inherited sideroblastic anemia. The defective ALAS2 activity in bone-marrow erythroblasts diminishes heme biosynthesis, leading to insufficient protoporphyrin IX to use all the available Fe. Most of the Fe deposited in perinuclear mitochondria of ringed sideroblasts is stored in the recently identified mitochondrial ferritin (Cazzola et al., 2003; Nie et al., 2005) . Iron overload disturbs cellular reduction-oxidation state and results in the shortening of the cellular lifetime. This causes expansion of the erythroid marrow, and ineffective erythropoiesis, pointing out to the role of ALAS2 in the cellular differentiation and survival of erythroid cells. Ineffective erythropoiesis also results in increased Fe absorption and the subsequent continuous accumulation of Fe in tissues.
In most cases, the mutation in ALAS2 gene appears to affect the affinity of the enzyme for its cofactor, pyridoxal 5 0 -phosphate, (Cox et al., 1994; Cotter et al., 1999) and these patients are, to some extent, responsive to pyridoxine, which is metabolized to pyridoxal 5 0 -phosphate. In some families, the ALAS2 gene mutation either decreases the processing or the stability of the enzyme, leading to reduction of its level (Furuyama et al., 1997) , or abrogates its interaction with protein partners (Furuyama and Sassa, 2000) , thus rendering patients resistant to pyridoxine supplementation (Astner et al., 2005) . Animal models for XLSA have been developed in mice and zebrafish by disruption of ALAS2 Mitochondria in hematopoiesis and hematological diseases M Fontenay et al gene homolog (Nakajima et al., 1999; Yamamoto and Nakajima, 2000) . An intriguing and still unexplained difference between the human disease and the mouse model is the absence of ring sideroblasts in the mouse models of ALAS2 deficiency (Harigae et al., 2003) . At least in humans, inhibition of heme synthesis leads to mitochondrial Fe accumulation, suggesting that the end product of the heme biosynthetic pathway regulates entry of Fe into the mitochondrion (Richardson et al., 1996) .
The four next steps of heme biosynthesis take place in the cytosol, leading to coproporphyrinogen III that is decarboxylated in the intermembrane space of the mitochondria to generate protoporphyrinogen IX. The seventh step, catalysed by a protein of the inner mitochondrial membrane, generates protoporphyrin IX in which Fe 2 þ ions loading under control of the ferrochelatase in the mitochondrial matrix represents the last step in heme biosynthesis (Ponka, 1999) . The expression of the mitochondrial (Fe-S)-containing protein, ferrochelatase, is positively regulated by the half-type ATPbinding cassette (ABC) transporter, ABCB7, the functional homolog of yeast Atm1p (Taketani et al., 2003) .
In human beings, defects in ABCB7 cause the mitochondrial accumulation of Fe in an inherited disease known as XLSA with ataxia (XLSA-A), which associates a nonprogressive ataxia in early childhood, elevated free erythrocyte protoporphyrin IX levels and mild hypochromic microcytic anemia (Shimada et al., 1998) . Mutations in ABCB7 induce a disruption in the maturation of cytosolic (Fe-S) clusters, indicating that an essential function of mitochondria is to supply (Fe-S) clusters to the cytosol. Disruption of this process results in the mitochondrial Fe loading (Taketani et al., 2003) . The ataxia observed in ABCB7-deficient patients may be related to the mitochondrial damage generated by Fe loading in neural cells, which distinguishes these patients from ALAS2-deficient patients as the expression of ALAS2 is confined to erythroid cells and the synthesis of heme in neural tissues is mediated by ALAS1. Another half-type ABC protein, ABC-me, which is highly expressed in tissues related to hematopoiesis, has been identified (Shirihai et al., 2000) but whether this mitochondrial transporter is responsible for an inherited sideroblastic anemia remains unknown.
Some similarities exist between XLSA-A and Friedreich ataxia. In this latter disease, mutations in the gene encoding frataxin, a protein associated with the mitochondrial inner membrane and involved in (Fe-S) cluster formation, induces Fe accumulation in the mitochondria of non-erythroid cells such as neurons and cardiomyocytes (Campuzano et al., 1996; Pandolfo, 2003) . However, no anemia is observed in Friedreich ataxia and Fe does not accumulate in mitochondria of erythroid cells because frataxin levels are low in these cells to favor Fe utilization for heme production (Becker et al., 2002; Napier et al., 2005) .
In mice, sideroblastic anemias have been reproduced also by mutating the mitochondrial membrane protein, flexed tail (Fleming et al., 2001) , and by deleting the antioxydant protein superoxide dismutase-2 that protects cells against mitochondrial superoxide (Friedman et al., 2004) . In yeast, mitochondrial Fe accumulation with altered mitochondrial functions can be reproduced by mutating any of the enzymes of the (Fe-S) cluster assembly pathway (Lill and Kispal, 2000) . In addition, mutation in the yeast ABC transporter Atm1p leads to mtDNA damage, indicating a link between Fe homeostasis and integrity of mtDNA. Altogether, observations made in animal models of sideroblastic anemias as well as in human diseases indicate the central role of mitochondrial Fe accumulation in the pathophysiology of these inherited diseases.
In acquired sideroblastic anemias, no defect in enzymes involved in heme synthesis and Fe export has been so far identified, that is ALAS2 as well as ABC transporter genes are not mutated and concentrations of ferrochelatase are normal (Pasanen et al., 1981) . Iron accumulation in ferric Fe 3 þ form suggested a dysfunction in the respiratory chain (Grasso et al., 1980) . Mutations of the subunit I of cytochrome c oxidase gene, encoded by the mtDNA, were described in some RARS, but whether this later event interferes with Fe 3 þ reduction remains to be proven (Gattermann et al., 2002) .
Mitochondria, caspases and hematopoietic cell differentiation
Caspases are cysteine proteases expressed in virtually all animal cells. These enzymes play an essential role in many forms of cell death by apoptosis. They also demonstrate several non-apoptotic functions, for example some of them are involved in the maturation of inflammatory cytokines, the response to DNA damage (Zhivotovsky and Orrenius, 2005) , the regulation of cell lipid content (Logette et al., 2005) , the proliferation of T and B cells (Woo et al., 2003) and the differentiation of specific cell types (Launay et al., 2005) .
Erythropoiesis encompasses the differentiation of hematopoietic stem cells into recognizable erythroid blasts, culminating with enucleation to form the reticulocytes. Erythropoiesis is promoted by the hormone erythropoietin (Epo) and a transient activation of several caspases is required for Epo-induced erythroid differentiation in both humans and mice (Zermati et al., 2001; Kolbus et al., 2002; Carlile et al., 2004) . In this context, caspases appear to be activated through a mitochondria-dependent pathway similar to that identified in various forms of apoptosis (Zermati et al., 2001; Kolbus et al., 2002) . This activation of caspases is in apparent contrast with Epo-mediated upregulation of the antiapoptotic protein Bcl-X L through activation of the transcription factor GATA-1 during terminal erythroid differentiation (Gregory et al., 1999; Motoyama et al., 1999) . The main function of Bcl-X L in this differentiation pathway is supposed to be the prevention of apoptosis during erythroid development (Wang et al., 2000) , for example by limiting differentiation-related caspase activation. Analysis of an erythroleukemia cell model of erythroid differentiation suggested that Bcl-X L was also required for heme synthesis in the mitochondria, independently of its antiapoptotic function (HafidMedheb et al., 2003) . This later function remains to be confirmed in normal erythropoiesis.
In erythroid cells undergoing apoptosis under Epo deprivation or death receptor stimulation, GATA-1 is cleaved by caspases and Bcl-X L expression decreases (De Maria et al., 1999) . On the other hand, GATA-1 remains uncleaved in erythroid cells undergoing terminal differentiation despite caspase activation (Zermati et al., 2001) , which could be related to protection of GATA-1 by a chaperone protein in Epo-stimulating cells (unpublished data). Altogether, these results suggest that the mitochondrial pathway to caspase activation is tightly regulated along the erythroid pathway of differentiation, a regulation that involves Bcl-X L and probably other Bcl-2-related proteins at the mitochondrion level (Aerbajinai et al., 2003) . Surprisingly enough, a membrane-associated Bcl-X L was reported also to protect mature erythrocytes, which lack mitochondria, from death (Walsh et al., 2002) .
Fas-associated death domain (FADD) protein and caspase-8 were proposed to play a role in the negative regulation of erythropoiesis through a feedback loop where mature erythroblasts, that express Fas-ligand, might exert a cytotoxic effect on immature erythroblasts expressing the death receptor Fas within the erythroblastic island (Varfolomeev et al., 1998; De Maria et al., 1999) . In Fas-stimulated immature erythroblasts, the transcription factor GATA-1 is cleaved by activated caspases, which impairs erythroid differentiation or leads to apoptosis, depending on Epo concentration in the environment.
In the megakaryocytic lineage, caspases are involved in thrombopoietin-induced megakaryocyte differentiation and proplatelet formation. Caspase activation identified along in vitro megakaryocytopoiesis and leading to GATA-1 and nuclear factor-erythroid-2 (NF-E2) cleavage appears to be a Fas-mediated negative regulatory mechanism similar to that described in erythroid cells (De Maria et al., 1999) whereas localized caspase-3 activation in the megakaryocyte cytoplasmic extensions called proplatelets may be mediated by cytochrome c released from the mitochondria and is prevented by Bcl-2 overexpression, which inhibits platelet formation (De Botton et al., 2002) .
In the monocytic lineage, caspases are required for the differentiation of peripheral blood monocytes into macrophages when cultured in the presence of macrophage colony-stimulating factor (M-CSF) whereas their activation is not requested for their differentiation into dendritic cells under exposure to granulocyte M-CSF and interleukin (IL)-4. Caspase activation in monocytes undergoing differentiation into macrophages involves the mitochondrial release of cytochrome c and Bcl-2 overexpression inhibits the differentiation process (Sordet et al., 2002) . Caspase-8 appears to be the apical enzyme in this pathway (Kang et al., 2004, and unpublished data) , and homozygous deletion of bid gene involved in death receptor signal amplification, induces a fatal, clonal malignancy closely resembling the human myelodysplastic/myeloproliferative disease known as chronic myelomonocytic leukemia (Zinkel et al., 2003) . Bcl-2 also protects neutrophil precursors from apoptosis as its expression is decreased in bonemarrow progenitor cells from patients with Kostmann's syndrome, a rare and severe congenital neutropenia in which administration of human recombinant granulocyte CSF restores Bcl-2 expression and normalizes the neutrophil count (Carlsson et al., 2004) .
A role for mitochondria in acquired myelodysplastic syndromes Acquired myelodysplastic syndromes are a heterogeneous group of clonal disorders of hematopoietic stem cells characterized by a hypercellular bone marrow with morphological features of dysplasia and peripheral blood cytopenias, mostly aregenerative anemia, and sometimes neutropenia and/or thrombocytopenia. A potential role for the mitochondria in these syndromes was recently suggested by analysis of the crimsonless (crs) zebrafish mutant that develop a myelodysplastic syndrome, as the crs gene encodes a mitochondrial heat shock protein (mthsp70/GRP75/mortalin) whose mutation enhances oxidative stress in blood cells (Craven et al., 2005) .
At early stages of acquired myelodysplastic syndromes, exacerbation of the physiological pathway to caspase activation in erythroid cells, even in the presence of elevated Epo concentrations, is responsible for a high rate of apoptosis, ineffective erythropoiesis and increased phagocytosis (Raza et al., 1995; Bouscary et al., 1997; Hellstrom-Lindberg et al., 2001; Shetty et al., 2002; Tehranchi et al., 2003; Testa, 2004) . Several observations argue for a role of the Fas-L/Fas pathway in this pathogenic event. First, both the death receptor and its ligand are overexpressed at the surface of bonemarrow cells from patients with early-stage myelodysplastic syndrome, including immature CD34 þ hematopoietic progenitors and more differentiated erythroid and granulo-monocytic precursors (Gersuk et al., 1996; Bouscary et al., 1997; Kitagawa et al., 1998) . Secondly, the Fas-mediated apoptotic pathway is functional in these cells as their Fas-dependent apoptosis can be triggered by an agonistic antibody (Claessens et al., 2002) . Third, lentivirus-mediated introduction of a dominant-negative mutant of the adapter FADD in CD34 þ cells from patients with a low-grade myelodysplastic syndrome prevents apoptosis of erythroid precursors grown from these CD34 þ cells in liquid medium (Claessens et al., 2005) . Interestingly, when the disease progresses to acute myeloid leukemia, Fas expression at the surface of hematopoietic cells decreases and, even though Fas-L remains expressed, it cannot induce apoptosis in the absence of its receptor (Bouscary et al., 1997; Kitagawa et al., 1998; Gupta et al., 1999; Claessens et al., 2002) .
A decrease in the mitochondrial transmembrane potential (Dc m ) was observed in bone-marrow cells from patients with myelodysplastic syndromes ( (Matthes et al., 2000; Berger et al., 2001 ) and unpublished data). This decrease is associated with the mitochondrial release of cytochrome c to the cytosol (Tehranchi et al., 2003) . The consequences of cytochrome c release are caspase-9 overactivation as compared to normal erythroid cells undergoing differentiation (Zermati et al., 2001) . Similarly, caspase-3 is clearly much more activated in myelodysplastic precursors as compared to their normal counterparts (Bouscary et al., 2000; Claessens et al., 2002; Matthes et al., 2002) . Cytochrome c-mediated activation of caspase-9 and downstream caspase-3 was further suggested by the protective effects of cell permeant peptide inhibitors (Tehranchi et al., 2003) .
The mitochondrial pathway to apoptosis is under the control of proteins of the Bcl-2 family. These proteins, which are defined by the presence of at least one Bcl-2 homology (BH) domain in their primary structure, can be classified into three groups with opposite effects on cell death. Proteins from the first group such as Bcl-2 and Bcl-X L are primarily localized to the mitochondria external membrane and prevent apoptotic cell death. Those from the two other groups are pro-apoptotic molecules. They include multi-BH domain proteins, mainly Bax and Bak, which are requested for mitochondria membrane permeabilization in response to a number of apoptotic stimuli (Lindsten et al., 2000; Wei et al., 2001) , and BH3-only proteins that are sentinels of cell damage and migrate to the mitochondria in response to these damage either to activate the proapoptotic proteins Bax and Bak or to inhibit antiapoptotic proteins such as Bcl-2 or Bcl-X L (Letai, 2005) . The expression of Bak and Bax remains unchanged in bonemarrow cells from patients with low-grade myelodysplastic syndromes as compared to control cells (Parker et al., 2000) , which does not preclude their involvement through conformational changes and dimerization, respectively. Bid and Bax were detected in active state during clonal erythroid cell differentiation, suggesting their involvement in the connection of Fas to the mitochondria in the pathway that leads to cytochrome c release (Claessens et al., 2003) . According to antiapoptotic proteins of the Bcl-2 family, the expression of Bcl-X L and Bcl-2 remains unchanged in low-grade myelodysplastic cells but Bcl-2 expression increases with the percentage of immature cells in the bone marrow (Parker et al., 2000; Claessens et al., 2002) .
Other proteins that regulate caspase activation include FADD-like interleukin-1-b-converting enzymeinhibitory protein (FLIP) long and short isoforms that prevent caspase-8 activation at the level of the deathinducing signaling complex) and some inhibitors of apoptosis proteins (IAPs) that trigger the degradation of caspase-3, -7 and -9 by the proteasome machinery. Neither the expression of FLIP nor that of IAPs were found significantly altered in bone-marrow cells from patients with early stage myelodysplastic syndromes (Yamamoto et al., 2004) . Conversely, an increase in the expression of FLIP L was associated with progression from early stage to blastic phase of the disease (Benesch et al., 2003) . The expression of several of the proteins that negatively regulate apoptosis depends on the transcriptional activity of nuclear factor (NF)-kB. It is now established that NF-kB can be constitutively activated as cells progress from low-to high-grade myelodysplasia and acute myeloid leukemia, suggesting that inhibitors of the NF-kB pathway may be interesting to test to reverse the disease progression (Braun et al., 2006; Kerbauy et al., 2005) .
Apoptosis of megaloblastic erythroblasts upon folate or cobalamine deficiency, apoptosis of erythroblasts from patients with b-thalassemia, parvovirus B19 infection or congenital aplastic anemia and anemia from patients with multiple myeloma or rheumatoid arthritis could also be related to amplification of a physiological, mitochondria-mediated, caspase activation associated with erythroid differentiation (Testa, 2004) . On the other hand, the thrombopenia observed in myelodysplastic patients was recently shown to be related to a necrosis-like, caspase-3-independent death of megakaryocytes (Houwerzijl et al., 2005) .
In some patients with chronic myelomonocytic leukemia, the differentiation of their peripheral blood monocytes upon M-CSF exposure is blocked upstream of caspases activation and it will be interesting to test whether molecules that target the mitochondria could restore caspase activation and subsequent cell differentiation of these patient monocytes into macrophages (S Cathelin and E Solary, personal data).
Mitochondrial changes upon malignant transformation
In contrast to sideroblastic anemias and early-stage myelodysplastic syndromes in which an excess of cell death is observed, malignant transformation is usually associated with an inhibition of apoptosis, for example transformation of early-stage to high-grade myelodysplastic syndromes is associated with a disappearance of the excess in bone-marrow cell death (Mufti, 2004) . Disease progression involves oncogenic mutations, for example Ras gene mutations, and DNA hypermethylation and histone deacetylation leading to changes in the expression of various genes, including genes encoding mitochondrial proteins.
In other malignant hematopoietic diseases, molecular changes that characterize malignant transformation can also occur at the mitochondrial level. The best-known example is follicular lymphoma whose occurrence involves a t(14;18) translocation leading to overexpression of Bcl-2 on the external membrane of the mitochondria. Other changes in the proteins of the Bcl-2 family include chromosomal translocation-independent overexpression of Bcl-2 in AMLs (Campos et al., 1993) and non-Hodgkin lymphomas (Hermine et al., 1996) , overexpression of the Bcl-2-related antiapoptotic protein Mcl-1 in relapsed AMLs (Kaufmann et al., 1998) and multiple myeloma (Derenne et al., 2002) , Bfl-1 in diffuse large-cell lymphomas (Shipp et al., 2002) , high Bcl-2 protein level and mutation in mcl-1 gene promoter in chronic lymphocytic leukemias (Moshynska et al., 2004) mutations of the bax gene (Meijerink et al., 1998) and changes in the pro-apoptotic to antiapoptotic Bcl-2 protein ratio (Schiller et al., 2002) . In addition, oncogenic viruses such as EpsteinBarr virus, which has been implicated in the causation of lymphomas, and Kaposi sarcoma herpes virus, HHV-8, which has been implicated in Castelman disease and lymphomas, encode Bcl-2 homologs that oppose cell death (Henderson et al., 1993; Cheng et al., 1997) .
A typical example is the deregulation of Mcl-1 expression in multiple myeloma cells. Multiple myeloma is an incurable disease characterized by an accumulation of malignant long-lived plasma cells. The role of Mcl-1, a short-lived protein that is rapidly induced and turned over (Michels et al., 2005) , in this accumulation was suggested by the specific ability of Mcl-1 antisense oligonucleotides to trigger apoptosis in malignant plasma cells (Derenne et al., 2002) . Mcl-1 mRNA and protein both have a short half-life and a rapid turn over (Gojo et al., 2002) . In multiple myeloma cells, Mcl-1 expression is highly regulated by IL-6 through the Janus kinase/signal transducersn and activators of transcription pathway (Puthier et al., 1999) , although it could become IL-6 independent as disease progresses (Jourdan et al., 2003; Zhang et al., 2003) . Mcl-1 expression is also upregulated by a interferon, vascular endothelial growth factor, Baff and April (Jourdan et al., 2000; Le Gouill et al., 2004; Moreaux et al., 2004) . Mitochondrial Mcl-1 is mainly associated with Bim (Gomez-Bougie et al., 2005b), a BH3-only protein involved in cytokinedependent survival pathways (Opferman et al., 2003) . This complex can be disrupted upon IL-6 deprivation, which may permit Bim to activate Bax and to trigger apoptosis (Gomez-Bougie et al., 2004) .
Mitochondria as a target for treating hematopoietic cell diseases
Therapeutic approaches aiming to decrease the mitochondrial pathway to death may be theoretically useful in sideroblastic anemias and early stage myelodysplastic syndromes. Several years ago, cyclosporin A, the undecapeptide widely used as an immunosuppressant in organ and bone-marrow transplantation, was shown to improve blood cell production in myelodysplastic syndromes, an effect that could be related to the ability of this compound to inhibit the mitochondrial permeability transition by interacting with cyclophylin D (Jonasova et al., 1998) but its potential toxicity, e.g. neurotoxicity and immunodepression, may limit its clinical use (Serkova et al., 2004; Waldmeier et al., 2002) . A modulation in the ratio of Bcl-2-related proteins in favor of antiapoptotic members proved efficient in decreasing apoptosis in animal models of myocardial or cerebral ischemia and chronic neurodegenerative diseases (Kostic et al., 1997; Azzouz et al., 2000; Bombrun et al., 2003; Sawada et al., 2003; Becattini et al., 2004; Weisleder et al., 2004) .
Antioxidants also showed promise for prevention of ischemia/reperfusion injury that involves apoptosis (Marczin et al., 2003) but their ability to affect apoptosis rate in erythroid diseases still remains to be determined. The erythroid apoptosis that characterizes myelodysplastic syndromes could be inhibited by growth factors such as Epo (Tehranchi et al., 2005) . The question remains opened of whether strategies aiming to inhibit cell death in early-stage myelodysplastic syndromes could favor accumulation of blast cells and transformation.
On the other hand, in transformed hematological diseases, chemotherapeutic agents are used to trigger death of malignant cells. Classical anticancer agents all induce apoptosis when tested on cell lines in vitro. They usually activate the intrinsic pathway to death that involves the mitochondria and downstream caspase activation, although a ligand-independent role for death receptors was also suggested (Micheau et al., 1999; Lacour et al., 2003) . In multiple myeloma cells exposed to cytotoxic drugs, Mcl-1 expression specifically decreases through either synthesis blockade (Raje et al., 2005) or proteasome degradation (Zhong et al., 2005) or caspase-mediated cleavage (Gomez-Bougie et al., 2005a) , depending on the stimulus, whereas Bcl-2 expression remains unchanged (Michels et al., 2005) . The disappearance of Mcl-1 releases Bim isoforms that trigger Bax activation and cytochrome c release. Conversely, the proteasome inhibitor bortezomib currently used for treating multiple myeloma, induces a raise in Mcl-1 protein level by inhibiting its degradation. The compound also causes an elevation of the BH3-only protein NOXA, a preferred partner for Mcl-1 (Fernandez et al., 2005) . If the increase in Mcl-1 is not offset by the accumulation of NOXA or other BH3-only proteins, a combination of Bortezomib with a specific inhibitor of Mcl-1 (Nencioni et al., 2005) or other mitochondriatargeting compounds could be beneficial.
Mitochondrion is one of the intracellular targets of several commonly used as well as currently developed chemotherapeutic agents. For example, adenine deoxynucleoside analogs commonly used for treating some lymphoid malignancies such as cladribine and 2-chlororo-2 0 -ara-fluorodeoxyadenosine (Genini et al., 2000) and arsenic trioxide, an old cytotoxic agents that proved efficient in treating acute promyelocytic leukemia (Kroemer and de The, 1999; Larochette et al., 1999; Sordet et al., 2001) . In acute promyelocytic leukemia cells, cellular toxicity of arsenic trioxide appears to mainly result from increased production of ROS, leading to the opening of the permeability transition pore complex, a decrease in mitochondrial membrane potential, cytochrome c release and caspase activation (Zhou et al., 2003; Chou et al., 2004) . Ascorbic acid can enhance the efficacy of arsenic trioxide by reducing intracellular glutathione concentrations and this combination is currently tested in elderly patients with acute myeloid leukemia when these patients are not able to withstand intensive chemotherapy. Other agents targeting the mitochondria include lonidamine (Belzacq et al., 2001 ) a dichlorinated derivative of indazole-3-carboxylic acid, which has been tested for treating B-cell malignancies (Tura et al., 1984) and for ex vivo purging of the bone marrow in autologous transplantation (Sandrelli et al., 1992) and CD437, a retinoic acid receptor gamma activator with therapeutic potential in myeloid leukemias (Marchetti et al., 1999) .
Apoptosis induced by cytotoxic agents in leukemic cell lines is often obtained in vitro at supra-pharmacological doses and the question of whether anticancer drugs trigger a mitochondria-dependent mode of cell death in vivo has been a matter of controversy. For example, clonogenic assays questioned the ability of overexpressed Bcl-2 to prevent cytotoxic agents from killing malignant cells as these assays did not always identify a Bcl-2-mediated resistance to anticancer drugs (Walker et al., 1997) . However, these assays do not distinguish cell death from cell cycle arrest and do not reproduce the tumor microenvironment. The best demonstration of a negative role for Bcl-2 in clinical response to chemotherapeutic drugs was provided by analysing a transplantable model of transgenic lymphoma in mice. It was shown that Bcl-2 overexpression could protect lymphoma cells from undergoing apoptosis in response to cyclophosphamide administration in vivo, thus decreasing the tumor response to the cytotoxic treatment (Schmitt et al., 2000) . In this animal model, cells overexpressing Bcl-2 can still die through a senescence-like mechanism but deletion of the cyclindependent kinase inhibitor p16, that plays a role in the senescent phenotype, still enhances the resistance to cyclophosphamide in vivo (Schmitt et al., 2002) . In addition, in a mouse model of B-lymphoblastic leukemia, downregulation of Bcl-2 transgene by doxycycline established the proof of principle that, under certain conditions, correction of an antiapoptotic defect at the mitochondria level could be lethal to malignant cells (Letai et al., 2004) .
Altogether, these data suggest that mitochondria involving apoptosis is a mode of death induced by anticancer drugs in vivo. The observations that mutations at the level of the mtDNA (Singh et al., 1999) and increased sequestration of free Ca 2 þ in the mitochondria (Chandra et al., 2002) were related to cell resistance to anticancer drugs in vivo, further argued for a role of the organelle in malignant cell death induces by chemotherapeutic drugs. When apoptosis is inhibited, malignant cells can die by other, possibly less efficient, mechanisms. In addition to apoptosis and senescence, several mode of cell death can be triggered by a cytotoxic agent, e.g. etoposide triggers a lysosome-mediated, mitochondria-independent death in the P39 myelomonocytic leukemic cells derived from a myelodysplastic syndrome (Fadeel et al., 1999; Hishita et al., 2001) .
Molecules developed to target the mitochondria
Based on previously reported observations, agents directly targeting components of the mitochondria have been identified or specifically designed to this function (Bouchier-Hayes et al., 2005) . For example, several peptides with a positively charged a-helical structure are attracted by and disrupt the negatively charged mitochondrial membrane without toxicity towards neutrally charged plasma membrane (Oren et al., 2002) . They include 14-amino-acid amphipathic peptides such as (KLAKLAK) 2 , sometimes coupled to specific cell targeting motifs (Ellerby et al., 1999) , the neuropeptide known as substance P (del Rio et al., 2001) and several viral proteins folded into a-helix (Takada et al., 1999; Jacotot et al., 2000) .
Other agents target mitochondrial membrane proteins involved in the formation of the permeability transition pore complex. One is the mitochondrial benzodiazepine receptor pBzR (Zamzami and Kroemer, 2001 ) that is targeted by the isoquinolone carboxamide derivative PK11195 and the benzodiazepine 4 0 -chlorodiazepam (R O5-4864). These agents behave as chemosensitizers, both in vitro and in animal models (Banker et al., 2002; Decaudin et al., 2002) . Another one is the adenosine nucleotide translocator (ANT) targeted by molecules such as MT-21 (Watabe et al., 2000) and the photosensitizer verteportfin (Belzacq et al., 2001) . A combination of lonidamide, that targets ANT, and diazepam that targets pBzR, diazepam, could be synergistically toxic (Oudard et al., 2003) . Some chemical agents cause depletion of mtDNA in mammalian cells, including lipophilic cations such as the rhodocyanin dye MKT-077 that selectively accumulate in the mitochondria (Weisberg et al., 1996) and the bifunctional intercalating anticancer drug ditercalinium (Fellous et al., 1988) . However, drugs interfering with mtDNA function could induce clinical symptoms similar to those observed in inherited mdDNA diseases. A number of other compounds that target the mitochondria are currently developed (for review, see Bouchier-Hayes et al., 2005) .
Bcl-2 itself is an attractive therapeutic target for antileukemic drugs as the protein is overexpressed in a variety of hematopoietic malignancies. Owing to the resistance conferred by Bcl-2 to most chemotherapeutic agents, Bcl-2 antagonists may sensitize Bcl-2 overexpressing cells to classical cytotoxic drugs. The first and most developed strategy involves antisense oligonucleotides which are chemically modified stretches of single-strand DNA forming specific RNA-DNA duplex with the targeted messenger RNA, thus leading to its RNase H-mediated cleavage and inhibition of the gene expression. An 18-mer phorphorothioate antisense oligonucleotide complementary of the first six codons of the initiating sequence of the human bcl-2 mRNA demonstrated encouraging preclinical results (Jansen et al., 1998) and was initially tested in patients with lymphoma, which identified some dose-limiting toxicities such as thrombocytopenia (likely due to the phosphorothioate backbone of the antisense molecule) and hypotension (Waters et al., 2000) . Phase I/II trials of Genasense in combination with classical cytotoxic drugs provided encouraging results (Rudin et al., 2004) but phase III trials in diseases such as chronic lymphocytic leukemias, multiple myelomas and melanomas did not demonstrate sufficient benefits to offset the toxicity and so far, the Federal Drug Administration in US did not approve Oblimersen as an anticancer drug (Letai, 2005) .
Several alternative approaches were developed to abrogate the expression of Bcl-2 or Bcl-X L proteins in malignant cells. Small peptide molecules that mimic the BH3 domain, a B16 amino-acid amphipathic a-helix that inserts into a hydrophobic crevice on the surface of antiapoptotic proteins, can suppress human myeloid leukemia growth in severe combined immunodeficient mice (Wang et al., 2000; Letai, 2005) . Small, nonpeptidic organic compounds that interact with the surface pocket of Bcl-2 (also called BH3 mimetics) have been identified through various strategies, for example ABT-737 was rationally designed (Oltersdorf et al., 2005) whereas GXO1 was selected by functional screening. Some of these molecules are currently developed in phase I/II trials such as GX01 in chronic lymphocytic leukemias.
Conclusions
Changes at the level of the mitochondria and associated proteins, mainly those of the Bcl-2 family, play a role in the appearance or in the progression of hematopoietic malignant diseases of both lymphoid and myeloid lineages by inhibiting cell death. Numerous strategies are currently developed to kill transformed cells or to sensitize them to classical chemotherapeutic agents by specifically targeting the mitochondria. On the other hand, many aspects of the mitochondrial functions in hematopoietic cells are still partly understood and their pathophysiological role suspected in various diseases has to be clarified. First, it will be necessary to determine whether mutations in mtDNA that accumulate with age account for the pathophysiology of acquired myelodysplastic syndromes. Secondly, the precise role of several recently identified mitochondrial proteins involved in Fe metabolism such as mitochondrial ferritin and fraxatin and their functions in sideroblastic anemias has to be further analysed. Third, the place of the mitochondrion in the caspase-dependent pathways to erythroid and macrophagic cell differentiation remains unclear. Better understanding of these various aspects of the mitochondrial functions may help to imagine strategies that prevent the mitochondria-mediated cell death that characterizes sideroblastic anemias and early-stage myelodysplastic syndromes.
